Home Sectors Healthcare Present Valuation: ANI Pharmaceuticals (NASDAQ: ANIP)

Present Valuation: ANI Pharmaceuticals (NASDAQ: ANIP)


ANI Pharmaceuticals trades as part of the biotechnology industry and is part of the healthcare sector. The company CEO is Arthur S. Przybyl. ANI Pharmaceuticals Inc is a specialty pharmaceutical company. The Company, together with its subsidiary is engaged in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals.

Previous Intraday Trading Performance:

The ANIP stock showed a previous change of 0.16% with an open at 64.46 and a close of 64.31. It reached an intraday high of 64.86 and a low of 63.98.

SeekingAlpha:  ANI Pharmaceuticals Inc. (ANIP) CEO Arthur Przybyl on Q4 2018 Results – Earnings Call Transcript


The stock has a market cap of $762.9m with 11.9m shares outstanding, of which the float is 10.5m shares. Trading volume reached 40,889 shares compared to its average volume of 77,073 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, ANI Pharmaceuticals shares returned 1.28% and in the past 30 trading days it returned 18.59%. Over three months, it changed 17.98%. In one year it has changed 2.49% and within that year its 52-week high was 72.81 and its 52-week low was 36.92. ANIP stock is 74.19% above its 52 Week Low.

Our calculations show a 200 day moving average of 58.13 and a 50 day moving average of 56.91. Currently ANIP stock is trading 10.64% above its 200 day moving average.

SeekingAlpha:  ANI Pharmaceuticals Q4 top line up 21%


The last annual fiscal EPS for the company was reported at 4.61 that ended on 31st of December 2018, which according to the previous close, that is a PE of 49.85. Based on 1 analyst estimate, the estimated EPS for the next quarter is 1.13. The TTM EPS is 4.61, which comes to a TTM PE of 13.95.

The following are the last four quarter reported earnings per share:
12-31-2018:  1.20
09-30-2018:  1.17
06-30-2018:  1.01
03-31-2018:  1.23

Base on our calculations, the intrinsic value per share is 123.47, which means it is possibly undervalued and has a margin of safety of 47.91%

Indicators to Watch:

Based on the latest filings, there is 87.00% of institutional ownership. Short-interest is 0, which is 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio is 0.00.

The current calculated beta is 2.42

SeekingAlpha:  ANI Pharmaceuticals beats by $0.08, beats on revenue

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 8.42%, return on assets is 3.72%, profit margin is 8.26%, price-to-sales is 4.01 and price-to-book is 3.86.

Company Scores:

All scores are out of six:
 2  :Valuation Score
 1  :Past Performance Score
 2  :Financial Strength Score
 4  :Future Growth Score
 0  :Dividend Score
 2  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.